Comparative efficacy of CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib in HR+/HER2- advanced breast cancer - PubMed
3 hours ago
- #CDK4/6 inhibitors
- #HR+/HER2- breast cancer
- #real-world efficacy
- The study compared the efficacy of three CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) combined with fulvestrant in 240 HR+/HER2- advanced breast cancer patients.
- In first-line treatment, ribociclib and abemaciclib showed a trend toward longer real-world progression-free survival (rwPFS) compared to palbociclib.
- Abemaciclib had a higher 24-month objective response rate (ORR) than palbociclib (P=0.049) and the longest duration of response (DoR), but also the greatest decline in patient-reported outcomes (31.31% meaningful deterioration).
- Common adverse events varied: neutropenia with palbociclib, hepatotoxicity/QT prolongation with ribociclib, and diarrhea with abemaciclib.
- No drug demonstrated comprehensive superiority across all endpoints; clinical decisions should consider multiple factors based on individualized medicine protocols.